Deregulation of the cell cycle is a hallmark of cancer, and research on cell cycle control has allowed identification of potential targets for anticancer treatment. Palbociclib is a selective inhibitor of the cyclin-dependent kinases ...
Selecting CDK4/6 inhibitors in advanced breast cancer
Identifying risk of recurrence in early breast cancer
Clinical trial data on CDK4/6 inhibitors in early and advanced breast cancer
Join the expert faculty in this roundtable
CDK4/6 inhibitors are a promising new class of drugs for hormone-receptor-positive breast cancer and have been shown to overcome and delay hormone resistance in advanced breast cancer.
Are you familiar with the clinical trial evidence that could help you to select the best cyclin dependent kinase 4/6 (CDK4/6) inhibitor for your metastatic breast cancer patient?
An overview of breast cancer stages and CDK4/6 inhibitors
Pfizer Inc. has announced it has completed the submission of a New Drug Application (NDA) to the FDA for palbociclib....
The National Institute of Health and Care Excellence (NICE) in draft guidance has rejected Ibrance (palbociclib) from Pfizer as a...